Zealand Pharma A/S (OTCMKTS:ZLDPF) Sees Large Increase in Short Interest

Zealand Pharma A/S (OTCMKTS:ZLDPF) was the recipient of a significant increase in short interest in the month of January. As of January 31st, there was short interest totalling 1,588,400 shares, an increase of 28.4% from the January 15th total of 1,237,500 shares. Based on an average daily trading volume, of 2,000 shares, the days-to-cover ratio is currently 794.2 days.

Analyst Upgrades and Downgrades

A number of research firms recently issued reports on ZLDPF. JPMorgan Chase & Co. began coverage on Zealand Pharma A/S in a research note on Friday, November 8th. They set an “overweight” rating on the stock. Cantor Fitzgerald upgraded Zealand Pharma A/S to a “strong-buy” rating in a research note on Tuesday, January 21st.

Zealand Pharma A/S Stock Performance

OTCMKTS:ZLDPF opened at $104.01 on Friday. The company has a debt-to-equity ratio of 0.03, a quick ratio of 35.49 and a current ratio of 35.49. Zealand Pharma A/S has a 52-week low of $67.58 and a 52-week high of $141.74. The firm has a market cap of $7.39 billion, a price-to-earnings ratio of -42.80 and a beta of 0.88. The business’s fifty day moving average is $102.19 and its 200 day moving average is $114.52.

Zealand Pharma A/S Company Profile

Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company offers Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon.